Cyrus Biotechnology

Cyrus Biotechnology, Inc.

12 Investors

Biotechnology, AI Drug Discovery

SEATTLE, WA

Cyrus Biotechnology is a biotechnology company that leverages its proprietary, AI-driven computational protein design platform to develop an internal pipeline of novel biotherapeutics. The company's primary focus is on creating therapies for autoimmune diseases and other serious unmet medical needs. Following a strategic pivot, Cyrus spun out its original software and services division into a new entity, Levitate Bio, to fully concentrate on its therapeutic development programs.

Products & Team

Internal Biotherapeutics Pipeline

Therapeutic DevelopmentSeed

Cyrus Biotechnology's core focus is the discovery and development of its own pipeline of novel protein-based drugs. The company uses its computational platform to design and optimize biologics for serious conditions, with a current emphasis on autoimmune diseases. Notable programs include an engineered IdeS for IgG-driven autoimmune disorders and a COVID-19 therapeutic candidate (sACE2.v2-Fc).

Value Proposition

Addresses serious unmet medical needs by creating best-in-class protein therapeutics that are computationally designed for enhanced safety and effectiveness.

Pain Points

The customer pain point is the lack of effective, safe, and long-lasting treatments for complex and debilitating autoimmune diseases.

De-risking of protein therapeutics by mitigating immunogenicityDesign of proteins with enhanced properties like extended half-lifeEngineering of biologics for greater stability and efficacy